Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2850)	2/8/2001 11:26:12 AM
From: Ian@SI	Read Replies (1) of 52153

Listened to SCIO's earnings conference call this morning. Natrecor: They and the analyst community are quite optimistic. Company already talking about plans for additional use with new label; getting unsolicited resumes from highly successful salespeople with desirable experience; will start to ramp up and train their sales force during late March / April; mentioned that they've received queries from doctors about where to purchase Natrecor. Anecdotal stuff, but encouraging all the same. And as you pointed out, the FDA does get to do their thing first. SCIO - 469: They seem very confident that they're not going to run into unexpected toxicity. Agree that it's very early days, however in addition to the RA application, they're also optimistic re CHF. In summary, I'm quite encouraged with their prospects and will probably hold most or all my shares at least until FDA ruling this summer. Replay available through their website at: sciosinc.com or at 1 888 203 1113 Passcode:422125#. Ian.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next